SPRINGWORKS THERAPEUTICS, INC. (SWTX): Price and Financial Metrics


Today's Latest Price: $37.41 USD

1.01 (-2.63%)

Updated Jul 16 12:13pm

Add SWTX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

SWTX Daily Price Range
SWTX 52-Week Price Range

SWTX Stock Price Chart Technical Analysis Charts

SWTX Price/Volume Stats

Current price $37.41 52-week high $49.79
Prev. close $38.42 52-week low $17.02
Day low $37.41 Volume 27,081
Day high $39.00 Avg. volume 162,151
50-day MA $39.51 Dividend yield N/A
200-day MA $30.94 Market Cap 1.61B


Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

SWTX Latest News Stream

Event/TimeNews Detail
Loading, please wait...

SWTX Latest Social Stream

Loading social stream, please wait...

View Full SWTX Social Stream

Latest SWTX News From Around the Web

Below are the latest news stories about SpringWorks Therapeutics Inc that investors may wish to consider to help them evaluate SWTX as an investment opportunity.

Hedge Funds Keep Buying SpringWorks Therapeutics, Inc. (SWTX)

In this article we will take a look at whether hedge funds think SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]

Yahoo | June 28, 2020

Dosing underway in SpringWorks' early-stage combination study in multiple myeloma

SpringWorks Therapeutics (SWTX) doses first patient in a Phase 1b clinical trial evaluating its investigational gamma secretase inhibitor, nirogacestat, in combination with GlaxoSmithKline’s (GSK) investigational anti-B-cell maturation antigen ((BCMA)) antibody-drug conjugate, belantamab mafodotin, in patients with relapsed or refractory multiple myeloma.The nirogacestat and belantamab mafodotin combination is being evaluated as...

Seeking Alpha | June 22, 2020

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple Myeloma

STAMFORD, Conn., June 22, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on…

GlobeNewswire | June 22, 2020

BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial

Preclinical data presented at the American Association for Cancer Research 2020 Virtual Annual Meeting II Ongoing Phase 1b/2 clinical trial on track to commence dose.

Yahoo | June 22, 2020

SpringWorks Therapeutics (SWTX) in Focus: Stock Moves 5.9% Higher

SpringWorks Therapeutics (SWTX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Yahoo | June 17, 2020

Read More 'SWTX' Stories Here

SWTX Price Returns

1-mo -20.46%
3-mo 35.30%
6-mo 5.47%
1-year N/A
3-year N/A
5-year N/A
YTD -2.81%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7436 seconds.